<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Times" color="#000000"/>
	<fontspec id="font1" size="12" family="Helvetica,Bold" color="#ffffff"/>
	<fontspec id="font2" size="10" family="Times,Italic" color="#000000"/>
	<fontspec id="font3" size="7" family="Times,Italic" color="#000000"/>
	<fontspec id="font4" size="9" family="Times,Italic" color="#000000"/>
	<fontspec id="font5" size="6" family="Times,Italic" color="#000000"/>
	<fontspec id="font6" size="10" family="Times" color="#000000"/>
	<fontspec id="font7" size="7" family="Times" color="#000000"/>
	<fontspec id="font8" size="11" family="Helvetica,Bold" color="#000000"/>
<text top="42" left="279" width="54" height="8" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">MacDONALD</text>
<text top="754" left="537" width="13" height="11" font="font1" id="p1_t2" reading_order_no="143" segment_no="3" tag_type="text"><b>87</b></text>
<text top="765" left="227" width="7" height="9" font="font2" id="p1_t3" reading_order_no="133" segment_no="18" tag_type="text"><i>C</i></text>
<text top="767" left="233" width="27" height="6" font="font3" id="p1_t4" reading_order_no="134" segment_no="18" tag_type="text"><i>URRENT</i></text>
<text top="765" left="260" width="10" height="9" font="font2" id="p1_t5" reading_order_no="135" segment_no="18" tag_type="text"><i> O</i></text>
<text top="767" left="269" width="32" height="6" font="font3" id="p1_t6" reading_order_no="136" segment_no="18" tag_type="text"><i>NCOLOGY</i></text>
<text top="765" left="302" width="9" height="9" font="font2" id="p1_t7" reading_order_no="137" segment_no="18" tag_type="text"><i>—</i></text>
<text top="765" left="311" width="5" height="8" font="font4" id="p1_t8" reading_order_no="138" segment_no="18" tag_type="text"><i>V</i></text>
<text top="767" left="316" width="22" height="6" font="font5" id="p1_t9" reading_order_no="139" segment_no="18" tag_type="text"><i>OLUME</i></text>
<text top="765" left="338" width="22" height="8" font="font4" id="p1_t10" reading_order_no="140" segment_no="18" tag_type="text"><i> 14, N</i></text>
<text top="767" left="359" width="21" height="6" font="font5" id="p1_t11" reading_order_no="141" segment_no="18" tag_type="text"><i>UMBER</i></text>
<text top="765" left="381" width="7" height="8" font="font4" id="p1_t12" reading_order_no="142" segment_no="18" tag_type="text"><i> 3</i></text>
<text top="84" left="73" width="96" height="9" font="font6" id="p1_t13" reading_order_no="1" segment_no="1" tag_type="text">Why “competition”?</text>
<text top="95" left="73" width="221" height="9" font="font6" id="p1_t14" reading_order_no="2" segment_no="4" tag_type="text">Most clinical trials are sponsored by pharmaceu-</text>
<text top="105" left="55" width="239" height="9" font="font6" id="p1_t15" reading_order_no="3" segment_no="4" tag_type="text">tical firms. For example, in 2005, our Institutional</text>
<text top="117" left="55" width="239" height="9" font="font6" id="p1_t16" reading_order_no="4" segment_no="4" tag_type="text">Review Board at McGill University received 42 on-</text>
<text top="128" left="55" width="239" height="9" font="font6" id="p1_t17" reading_order_no="5" segment_no="4" tag_type="text">cology studies, of which 30 were industry-sponsored</text>
<text top="138" left="55" width="239" height="9" font="font6" id="p1_t18" reading_order_no="6" segment_no="4" tag_type="text">submissions. Sponsoring companies are usually in-</text>
<text top="150" left="55" width="239" height="9" font="font6" id="p1_t19" reading_order_no="7" segment_no="4" tag_type="text">terested in conducting trials with narrow inclusion</text>
<text top="161" left="55" width="239" height="9" font="font6" id="p1_t20" reading_order_no="8" segment_no="4" tag_type="text">criteria. These “fastidious” trials (defined as “using</text>
<text top="171" left="55" width="239" height="9" font="font6" id="p1_t21" reading_order_no="9" segment_no="4" tag_type="text">homogeneous groups, reducing or eliminating ambi-</text>
<text top="183" left="55" width="29" height="9" font="font6" id="p1_t22" reading_order_no="10" segment_no="4" tag_type="text">guity”</text>
<text top="181" left="84" width="6" height="6" font="font7" id="p1_t23" reading_order_no="11" segment_no="4" tag_type="text"> 3</text>
<text top="183" left="90" width="204" height="9" font="font6" id="p1_t24" reading_order_no="12" segment_no="4" tag_type="text">) are designed to examine the use of a spe-</text>
<text top="194" left="55" width="239" height="9" font="font6" id="p1_t25" reading_order_no="13" segment_no="4" tag_type="text">cific therapy in a carefully controlled environment,</text>
<text top="204" left="55" width="239" height="9" font="font6" id="p1_t26" reading_order_no="14" segment_no="4" tag_type="text">leaving little doubt that any observed efficacy directly</text>
<text top="216" left="55" width="239" height="9" font="font6" id="p1_t27" reading_order_no="15" segment_no="4" tag_type="text">relates to the tested product. This aim is sensible, and</text>
<text top="227" left="55" width="239" height="9" font="font6" id="p1_t28" reading_order_no="16" segment_no="4" tag_type="text">expected by regulatory authorities, but it leads to a</text>
<text top="237" left="55" width="239" height="9" font="font6" id="p1_t29" reading_order_no="17" segment_no="4" tag_type="text">trial milieu that may not reflect the general practice</text>
<text top="249" left="55" width="239" height="9" font="font6" id="p1_t30" reading_order_no="18" segment_no="4" tag_type="text">of oncology. “Pragmatic” trials—defined as those that</text>
<text top="260" left="55" width="239" height="9" font="font6" id="p1_t31" reading_order_no="19" segment_no="4" tag_type="text">“would incorporate heterogeneity, occasional or fre-</text>
<text top="270" left="55" width="239" height="9" font="font6" id="p1_t32" reading_order_no="20" segment_no="4" tag_type="text">quent ambiguity, and other ‘messy’ aspects of clini-</text>
<text top="282" left="55" width="58" height="9" font="font6" id="p1_t33" reading_order_no="21" segment_no="4" tag_type="text">cal practice”</text>
<text top="280" left="114" width="6" height="6" font="font7" id="p1_t34" reading_order_no="22" segment_no="4" tag_type="text"> 3</text>
<text top="282" left="120" width="174" height="9" font="font6" id="p1_t35" reading_order_no="23" segment_no="4" tag_type="text"> are more relevant to actual oncology</text>
<text top="293" left="55" width="239" height="9" font="font6" id="p1_t36" reading_order_no="24" segment_no="4" tag_type="text">practice, but are less commonly conducted. The pro-</text>
<text top="303" left="55" width="239" height="9" font="font6" id="p1_t37" reading_order_no="25" segment_no="4" tag_type="text">tocols for fastidious trials usually contain an exclu-</text>
<text top="315" left="55" width="239" height="9" font="font6" id="p1_t38" reading_order_no="26" segment_no="4" tag_type="text">sion clause with wording along the following lines:</text>
<text top="326" left="55" width="239" height="9" font="font6" id="p1_t39" reading_order_no="27" segment_no="4" tag_type="text">“Concomitant employment of other experimental</text>
<text top="336" left="55" width="239" height="9" font="font6" id="p1_t40" reading_order_no="28" segment_no="4" tag_type="text">therapies during the course of the clinical trial is</text>
<text top="348" left="55" width="53" height="9" font="font6" id="p1_t41" reading_order_no="29" segment_no="4" tag_type="text">prohibited”</text>
<text top="346" left="108" width="6" height="6" font="font7" id="p1_t42" reading_order_no="30" segment_no="4" tag_type="text"> 3</text>
<text top="348" left="114" width="3" height="9" font="font6" id="p1_t43" reading_order_no="31" segment_no="4" tag_type="text">.</text>
<text top="359" left="73" width="221" height="9" font="font6" id="p1_t44" reading_order_no="32" segment_no="8" tag_type="text">Inherently, a paradox is evident. The cancer com-</text>
<text top="369" left="55" width="239" height="9" font="font6" id="p1_t45" reading_order_no="33" segment_no="8" tag_type="text">munity believes that research into palliation and</text>
<text top="381" left="55" width="192" height="9" font="font6" id="p1_t46" reading_order_no="34" segment_no="8" tag_type="text">symptom control deserves a high priority</text>
<text top="379" left="247" width="6" height="6" font="font7" id="p1_t47" reading_order_no="35" segment_no="8" tag_type="text"> 4</text>
<text top="381" left="253" width="41" height="9" font="font6" id="p1_t48" reading_order_no="36" segment_no="8" tag_type="text"> and that</text>
<text top="392" left="55" width="239" height="9" font="font6" id="p1_t49" reading_order_no="37" segment_no="8" tag_type="text">that research should commence with the onset of a</text>
<text top="402" left="55" width="239" height="9" font="font6" id="p1_t50" reading_order_no="38" segment_no="8" tag_type="text">symptom (for example, as soon as a weight-losing</text>
<text top="414" left="55" width="239" height="9" font="font6" id="p1_t51" reading_order_no="39" segment_no="8" tag_type="text">patient with lung cancer presents with disease). How-</text>
<text top="425" left="55" width="239" height="9" font="font6" id="p1_t52" reading_order_no="40" segment_no="8" tag_type="text">ever, the same patient cannot go on a symptom con-</text>
<text top="435" left="55" width="239" height="9" font="font6" id="p1_t53" reading_order_no="41" segment_no="8" tag_type="text">trol trial if enrolled in a chemotherapy study, because</text>
<text top="447" left="55" width="239" height="9" font="font6" id="p1_t54" reading_order_no="42" segment_no="8" tag_type="text">participation in another clinical trial is proscribed.</text>
<text top="458" left="55" width="239" height="9" font="font6" id="p1_t55" reading_order_no="43" segment_no="8" tag_type="text">Consequently, late in the course of illness, a small</text>
<text top="468" left="55" width="239" height="9" font="font6" id="p1_t56" reading_order_no="44" segment_no="8" tag_type="text">coterie of exhausted patients with profound weight</text>
<text top="480" left="55" width="239" height="9" font="font6" id="p1_t57" reading_order_no="45" segment_no="8" tag_type="text">loss may now be asked if they wish to consider en-</text>
<text top="491" left="55" width="239" height="9" font="font6" id="p1_t58" reading_order_no="46" segment_no="8" tag_type="text">listing in a cachexia trial. But is this trial hierarchy</text>
<text top="501" left="55" width="36" height="9" font="font6" id="p1_t59" reading_order_no="47" segment_no="8" tag_type="text">logical?</text>
<text top="513" left="73" width="221" height="9" font="font6" id="p1_t60" reading_order_no="48" segment_no="11" tag_type="text">Exclusion of patients from participation in two</text>
<text top="524" left="55" width="239" height="9" font="font6" id="p1_t61" reading_order_no="49" segment_no="11" tag_type="text">simultaneous trials is usually justified for these</text>
<text top="534" left="55" width="38" height="9" font="font6" id="p1_t62" reading_order_no="50" segment_no="11" tag_type="text">reasons:</text>
<text top="557" left="55" width="4" height="9" font="font6" id="p1_t63" reading_order_no="51" segment_no="13" tag_type="list">•</text>
<text top="557" left="73" width="221" height="9" font="font6" id="p1_t64" reading_order_no="52" segment_no="13" tag_type="list">Regulatory authorities will not permit simulta-</text>
<text top="567" left="73" width="56" height="9" font="font6" id="p1_t65" reading_order_no="53" segment_no="13" tag_type="list">neous trials.</text>
<text top="579" left="55" width="4" height="9" font="font6" id="p1_t66" reading_order_no="54" segment_no="15" tag_type="list">•</text>
<text top="579" left="73" width="221" height="9" font="font6" id="p1_t67" reading_order_no="55" segment_no="15" tag_type="list">Participation in two trials will present confound-</text>
<text top="590" left="73" width="221" height="9" font="font6" id="p1_t68" reading_order_no="56" segment_no="15" tag_type="list">ing information that will make it impossible for</text>
<text top="600" left="73" width="221" height="9" font="font6" id="p1_t69" reading_order_no="57" segment_no="15" tag_type="list">the pharmaceutical firm to properly study the ef-</text>
<text top="612" left="73" width="221" height="9" font="font6" id="p1_t70" reading_order_no="58" segment_no="15" tag_type="list">ficacy of the drug or drug and radiotherapy com-</text>
<text top="623" left="73" width="221" height="9" font="font6" id="p1_t71" reading_order_no="59" segment_no="15" tag_type="list">bination of interest and to accurately assign</text>
<text top="633" left="73" width="83" height="9" font="font6" id="p1_t72" reading_order_no="60" segment_no="15" tag_type="list">adverse reactions.</text>
<text top="656" left="73" width="221" height="9" font="font6" id="p1_t73" reading_order_no="61" segment_no="16" tag_type="text">These excellent reasons fail to take note of cer-</text>
<text top="666" left="55" width="239" height="9" font="font6" id="p1_t74" reading_order_no="62" segment_no="16" tag_type="text">tain confounding facts. Many patients with advanced</text>
<text top="678" left="55" width="239" height="9" font="font6" id="p1_t75" reading_order_no="63" segment_no="16" tag_type="text">cancer are using a variety of untested combinations</text>
<text top="689" left="55" width="239" height="9" font="font6" id="p1_t76" reading_order_no="64" segment_no="16" tag_type="text">of diet, supplements, vitamins, herbs, naturopathic</text>
<text top="699" left="55" width="112" height="9" font="font6" id="p1_t77" reading_order_no="65" segment_no="16" tag_type="text">products, yoga, and so on</text>
<text top="698" left="167" width="6" height="6" font="font7" id="p1_t78" reading_order_no="66" segment_no="16" tag_type="text"> 5</text>
<text top="699" left="173" width="121" height="9" font="font6" id="p1_t79" reading_order_no="67" segment_no="16" tag_type="text">. Pharmaceutical trials have</text>
<text top="711" left="55" width="239" height="9" font="font6" id="p1_t80" reading_order_no="68" segment_no="16" tag_type="text">not usually controlled for these widespread potential</text>
<text top="722" left="55" width="239" height="9" font="font6" id="p1_t81" reading_order_no="69" segment_no="16" tag_type="text">confounders. Moreover, the populations at risk for</text>
<text top="84" left="318" width="239" height="9" font="font6" id="p1_t82" reading_order_no="70" segment_no="2" tag_type="text">cancer tend to be older, and they often have comor-</text>
<text top="95" left="318" width="239" height="9" font="font6" id="p1_t83" reading_order_no="71" segment_no="2" tag_type="text">bid conditions—notably diabetes, hypertension, car-</text>
<text top="105" left="318" width="239" height="9" font="font6" id="p1_t84" reading_order_no="72" segment_no="2" tag_type="text">diovascular disease, and chronic obstructive</text>
<text top="117" left="318" width="239" height="9" font="font6" id="p1_t85" reading_order_no="73" segment_no="2" tag_type="text">pulmonary disease. Patients with these disorders are</text>
<text top="128" left="318" width="239" height="9" font="font6" id="p1_t86" reading_order_no="74" segment_no="2" tag_type="text">thus receiving a wide variety of drugs that could af-</text>
<text top="138" left="318" width="93" height="9" font="font6" id="p1_t87" reading_order_no="75" segment_no="2" tag_type="text">fect disease activity</text>
<text top="137" left="411" width="14" height="6" font="font7" id="p1_t88" reading_order_no="76" segment_no="2" tag_type="text"> 6–8</text>
<text top="138" left="425" width="132" height="9" font="font6" id="p1_t89" reading_order_no="77" segment_no="2" tag_type="text"> and certainly may interfere</text>
<text top="150" left="318" width="239" height="9" font="font6" id="p1_t90" reading_order_no="78" segment_no="2" tag_type="text">with drug metabolism. Information on these agents</text>
<text top="161" left="318" width="239" height="9" font="font6" id="p1_t91" reading_order_no="79" segment_no="2" tag_type="text">and their relevance usually does not appear in study</text>
<text top="171" left="318" width="35" height="9" font="font6" id="p1_t92" reading_order_no="80" segment_no="2" tag_type="text">reports.</text>
<text top="183" left="336" width="221" height="9" font="font6" id="p1_t93" reading_order_no="81" segment_no="5" tag_type="text">Excluding careful clinical research observations</text>
<text top="194" left="318" width="239" height="9" font="font6" id="p1_t94" reading_order_no="82" segment_no="5" tag_type="text">on agents aimed at helping control symptoms, while</text>
<text top="204" left="318" width="239" height="9" font="font6" id="p1_t95" reading_order_no="83" segment_no="5" tag_type="text">ignoring the chaotic, uncontrolled potential effects</text>
<text top="216" left="318" width="239" height="9" font="font6" id="p1_t96" reading_order_no="84" segment_no="5" tag_type="text">of alternative and non-cancer-related therapies on</text>
<text top="227" left="318" width="239" height="9" font="font6" id="p1_t97" reading_order_no="85" segment_no="5" tag_type="text">drug and radiotherapy response is therefore illogi-</text>
<text top="237" left="318" width="239" height="9" font="font6" id="p1_t98" reading_order_no="86" segment_no="5" tag_type="text">cal. From a statistical point of view, patients who</text>
<text top="249" left="318" width="239" height="9" font="font6" id="p1_t99" reading_order_no="87" segment_no="5" tag_type="text">are also engaged in a symptom control trial can be</text>
<text top="260" left="318" width="239" height="9" font="font6" id="p1_t100" reading_order_no="88" segment_no="5" tag_type="text">readily stratified, although trials may then need to</text>
<text top="270" left="318" width="43" height="9" font="font6" id="p1_t101" reading_order_no="89" segment_no="5" tag_type="text">be larger.</text>
<text top="282" left="336" width="221" height="9" font="font6" id="p1_t102" reading_order_no="90" segment_no="6" tag_type="text">We worship at the “evidence based” altar. Many</text>
<text top="293" left="318" width="239" height="9" font="font6" id="p1_t103" reading_order_no="91" segment_no="6" tag_type="text">of our symptom control trials are lightly regarded</text>
<text top="303" left="318" width="239" height="9" font="font6" id="p1_t104" reading_order_no="92" segment_no="6" tag_type="text">because of small patient enrolment and high dropout</text>
<text top="315" left="318" width="239" height="9" font="font6" id="p1_t105" reading_order_no="93" segment_no="6" tag_type="text">rates from death and increasing frailty. Here are some</text>
<text top="326" left="318" width="239" height="9" font="font6" id="p1_t106" reading_order_no="94" segment_no="6" tag_type="text">examples from two recent studies published by lead-</text>
<text top="336" left="318" width="158" height="9" font="font6" id="p1_t107" reading_order_no="95" segment_no="6" tag_type="text">ers in the anorexia–cachexia field:</text>
<text top="359" left="318" width="4" height="9" font="font6" id="p1_t108" reading_order_no="96" segment_no="7" tag_type="list">•</text>
<text top="359" left="336" width="103" height="9" font="font6" id="p1_t109" reading_order_no="97" segment_no="7" tag_type="list">Fearon and colleagues</text>
<text top="357" left="439" width="6" height="6" font="font7" id="p1_t110" reading_order_no="98" segment_no="7" tag_type="list"> 9</text>
<text top="359" left="445" width="112" height="9" font="font6" id="p1_t111" reading_order_no="99" segment_no="7" tag_type="list"> recently reported on the</text>
<text top="369" left="336" width="221" height="9" font="font6" id="p1_t112" reading_order_no="100" segment_no="7" tag_type="list">efficacy of two doses of an omega-3 fatty acid</text>
<text top="381" left="336" width="221" height="9" font="font6" id="p1_t113" reading_order_no="101" segment_no="7" tag_type="list">on pancreatic cancer–induced cachexia. A robust</text>
<text top="392" left="336" width="221" height="9" font="font6" id="p1_t114" reading_order_no="102" segment_no="7" tag_type="list">effect was not found, only a favourable trend at</text>
<text top="402" left="336" width="221" height="9" font="font6" id="p1_t115" reading_order_no="103" segment_no="7" tag_type="list">the level of a 2-g dose of eicosapentaenoic acid.</text>
<text top="414" left="336" width="221" height="9" font="font6" id="p1_t116" reading_order_no="104" segment_no="7" tag_type="list">The mean weight loss on trial entrance was 18%,</text>
<text top="425" left="336" width="221" height="9" font="font6" id="p1_t117" reading_order_no="105" segment_no="7" tag_type="list">and the dropout rate among these profoundly ill</text>
<text top="435" left="336" width="217" height="9" font="font6" id="p1_t118" reading_order_no="106" segment_no="7" tag_type="list">patients was approximately 50% over 8 weeks.</text>
<text top="447" left="318" width="4" height="9" font="font6" id="p1_t119" reading_order_no="107" segment_no="9" tag_type="list">•</text>
<text top="447" left="336" width="158" height="9" font="font6" id="p1_t120" reading_order_no="108" segment_no="9" tag_type="list">The recent article by Strasser <i>et al.</i></text>
<text top="445" left="494" width="10" height="6" font="font7" id="p1_t121" reading_order_no="109" segment_no="9" tag_type="list"> 10</text>
<text top="447" left="504" width="53" height="9" font="font6" id="p1_t122" reading_order_no="110" segment_no="9" tag_type="list"> on cannab-</text>
<text top="458" left="336" width="221" height="9" font="font6" id="p1_t123" reading_order_no="111" segment_no="9" tag_type="list">inoid use in combating anorexia had a 32% drop-</text>
<text top="468" left="336" width="221" height="9" font="font6" id="p1_t124" reading_order_no="112" segment_no="9" tag_type="list">out rate in 8 weeks; the study population had a</text>
<text top="480" left="336" width="203" height="9" font="font6" id="p1_t125" reading_order_no="113" segment_no="9" tag_type="list">mean weight loss of 11.9% upon enrolment.</text>
<text top="501" left="336" width="221" height="9" font="font6" id="p1_t126" reading_order_no="114" segment_no="10" tag_type="text">We will not advance cachexia research until we</text>
<text top="513" left="318" width="239" height="9" font="font6" id="p1_t127" reading_order_no="115" segment_no="10" tag_type="text">can invite people with early weight loss to consider</text>
<text top="524" left="318" width="82" height="9" font="font6" id="p1_t128" reading_order_no="116" segment_no="10" tag_type="text">trial participation.</text>
<text top="545" left="318" width="225" height="10" font="font8" id="p1_t129" reading_order_no="117" segment_no="12" tag_type="title"><b>OBLIGATION TO DEVELOPING COUNTRIES</b></text>
<text top="567" left="318" width="239" height="9" font="font6" id="p1_t130" reading_order_no="118" segment_no="14" tag_type="text">Recent advances have come at a cost—a cost passed</text>
<text top="579" left="318" width="239" height="9" font="font6" id="p1_t131" reading_order_no="119" segment_no="14" tag_type="text">on to the health system, or now, frequently, to the</text>
<text top="590" left="318" width="239" height="9" font="font6" id="p1_t132" reading_order_no="120" segment_no="14" tag_type="text">patient as governments lag in picking up the tab for</text>
<text top="600" left="318" width="239" height="9" font="font6" id="p1_t133" reading_order_no="121" segment_no="14" tag_type="text">non-curative, extraordinarily expensive therapies that</text>
<text top="612" left="318" width="239" height="9" font="font6" id="p1_t134" reading_order_no="122" segment_no="14" tag_type="text">may modestly prolong survival for a select group of</text>
<text top="623" left="318" width="239" height="9" font="font6" id="p1_t135" reading_order_no="123" segment_no="14" tag_type="text">patients. To paraphrase the Etruscan general Pyrrhus’</text>
<text top="633" left="318" width="239" height="9" font="font6" id="p1_t136" reading_order_no="124" segment_no="14" tag_type="text">comment on winning a battle with the Romans at great</text>
<text top="645" left="318" width="239" height="9" font="font6" id="p1_t137" reading_order_no="125" segment_no="14" tag_type="text">cost to his army, “A few more pharmaceutical ad-</text>
<text top="656" left="318" width="239" height="9" font="font6" id="p1_t138" reading_order_no="126" segment_no="14" tag_type="text">vances like cetuximab and our cancer care system is</text>
<text top="666" left="318" width="49" height="9" font="font6" id="p1_t139" reading_order_no="127" segment_no="14" tag_type="text">bankrupt.”</text>
<text top="678" left="336" width="221" height="9" font="font6" id="p1_t140" reading_order_no="128" segment_no="17" tag_type="text">The costs of new anticancer agents create major</text>
<text top="689" left="318" width="239" height="9" font="font6" id="p1_t141" reading_order_no="129" segment_no="17" tag_type="text">dilemmas in Canada. What about resource-poor coun-</text>
<text top="699" left="318" width="239" height="9" font="font6" id="p1_t142" reading_order_no="130" segment_no="17" tag_type="text">tries such as those of the African continent? Those</text>
<text top="711" left="318" width="239" height="9" font="font6" id="p1_t143" reading_order_no="131" segment_no="17" tag_type="text">countries will never be able to pay for drugs like</text>
<text top="722" left="318" width="239" height="9" font="font6" id="p1_t144" reading_order_no="132" segment_no="17" tag_type="text">bevacizumab or cetuximab. Do we have an ethical</text>
</page>
</pdf2xml>
